Japanese encephalitis vaccine - Shandong Hengye Biotech

Drug Profile

Japanese encephalitis vaccine - Shandong Hengye Biotech

Alternative Names: Vero cell-derived inactivated Japanese encephalitis vaccine - Shandong Hengye Biotech

Latest Information Update: 20 Sep 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Shandong Hengye Biotech
  • Developer Jiangsu Provincial Center for Disease Control and Prevention; Shandong Hengye Biotech
  • Class Viral vaccines
  • Mechanism of Action Immunostimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase III Japanese encephalitis

Most Recent Events

  • 20 Sep 2017 Phase-III development for Japanese encephalitis (In infants, Prevention) is ongoing in China (Parenteral) (Shandong Hengye Biotech website, September 2017)
  • 18 Jul 2017 Shandong Hengye Biotech announces intention to carry out production registration declaration of vaccine for Japanese encephalitis (In infants, Prevention) in China in 2018 (Shandong Hengye Biotech website, September 2017)
  • 01 Oct 2014 Phase-III clinical trials in Japanese encephalitis (In infants, Prevention) in China (Parenteral)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top